Several analysts have recently updated their ratings and price targets for Juno Therapeutics (NASDAQ: JUNO):

  • 9/6/2017 – Juno Therapeutics is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $55.00 price target on the stock.
  • 9/5/2017 – Juno Therapeutics had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $54.00 price target on the stock, up previously from $35.00.
  • 8/31/2017 – Juno Therapeutics had its “reduce” rating reaffirmed by analysts at Standpoint Research.
  • 8/29/2017 – Juno Therapeutics was upgraded by analysts at Wedbush from a “neutral” rating to an “outperform” rating. They now have a $42.00 price target on the stock.
  • 8/29/2017 – Juno Therapeutics was upgraded by analysts at Raymond James Financial, Inc. from a “market perform” rating to an “outperform” rating. They now have a $45.00 price target on the stock.
  • 8/29/2017 – Juno Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/28/2017 – Juno Therapeutics was upgraded by analysts at BTIG Research from a “sell” rating to a “neutral” rating.
  • 8/28/2017 – Juno Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Juno reported wider-than-expected loss in second-quarter 2017 with revenue beating estimates. The company suffered a huge setback with discontinuation of the development of cancer candidate, JCAR015, due to the toxicity witnessed in a phase II ROCKET study. Also, increased competition in the immunotherapy space is a matter of concern for the company as several companies are looking to bring these treatments to the market. Juno’s pipeline candidates are still a few steps away from approval and hence, any setback would weigh heavily on the stock. Shares of the company have also underperformed the industry in the last one year. However, the company remains on track with its pipeline and continues to pursue acquisitions and licensing agreements. The company’s deal with Celgene for global development and commercialization of immunotherapies is encouraging.”
  • 8/14/2017 – Juno Therapeutics was upgraded by analysts at Vetr from a “strong sell” rating to a “sell” rating. They now have a $25.50 price target on the stock.
  • 8/10/2017 – Juno Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Juno reported wider-than-expected loss in second-quarter 2017 with revenue beating estimates. The company suffered a huge setback with discontinuation of the development of cancer candidate, JCAR015, due to the toxicity witnessed in a phase II ROCKET study. Also, increased competition in the immunotherapy space is a matter of concern for the company as several companies are looking to bring these treatments to the market. Juno’s pipeline candidates are still a few steps away from approval and hence, any setback would weigh heavily on the stock. Shares of the company have also underperformed the industry in the last one year. However, the company remains on track with its pipeline and continues to pursue acquisitions and licensing agreements. The company’s deal with Celgene for global development and commercialization of immunotherapies is encouraging.”
  • 8/7/2017 – Juno Therapeutics was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $28.47 price target on the stock.
  • 8/7/2017 – Juno Therapeutics had its price target raised by analysts at Morgan Stanley from $26.00 to $27.00. They now have an “equal weight” rating on the stock.
  • 8/3/2017 – Juno Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Juno remains on track with its pipeline candidates and continues to pursue acquisitions and licensing agreements. The company’s deal with Celgene for the global development and commercialization of immunotherapies is encouraging. Juno’s shares outperformed the Medical-Biomed/Genetics industry so far this year. However, the company recently suffered a huge setback as it discontinued the development of cancer candidate, JCAR015 due to the toxicity witnessed in a phase II ROCKET study. Moreover, increased competition in the immunotherapy space is a matter of concern for the company as several companies are looking to bring these treatments to the market. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters.”
  • 7/31/2017 – Juno Therapeutics was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $28.85 price target on the stock.
  • 7/24/2017 – Juno Therapeutics was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $28.85 price target on the stock.
  • 7/17/2017 – Juno Therapeutics was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $28.85 price target on the stock.

Shares of Juno Therapeutics, Inc. (NASDAQ JUNO) traded down 0.69% on Friday, reaching $44.30. 3,335,682 shares of the company’s stock traded hands. Juno Therapeutics, Inc. has a one year low of $17.52 and a one year high of $47.00. The firm’s market cap is $4.65 billion. The company’s 50-day moving average price is $33.60 and its 200 day moving average price is $26.98.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The firm had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. During the same period in the previous year, the business earned ($0.64) earnings per share. The firm’s revenue for the quarter was down 22.8% on a year-over-year basis. On average, equities analysts forecast that Juno Therapeutics, Inc. will post ($3.12) EPS for the current fiscal year.

In other Juno Therapeutics news, major shareholder Douglas K. Bratton sold 8,000,000 shares of the firm’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $27.00, for a total value of $216,000,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Anthony B. Evnin purchased 9,000 shares of the business’s stock in a transaction on Tuesday, June 20th. The stock was purchased at an average cost of $24.40 per share, with a total value of $219,600.00. Following the completion of the acquisition, the director now owns 66,301 shares in the company, valued at $1,617,744.40. The disclosure for this purchase can be found here. Over the last three months, insiders sold 8,119,219 shares of company stock valued at $220,455,844. Insiders own 15.26% of the company’s stock.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Receive News & Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.